hepatitis B
-
Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company
Warminster-based Arbutus Biopharma has ended a 4-year licensing deal worth up to $285 million with Qilu Pharmaceuticals, a Chinese drugmaker, writes John George for the…
-
Warminster’s Arbutus Biopharma Achieves Breakthrough in Hepatitis B Treatment
Warminster biotech company Arbutus Biopharma shared promising results from its latest study on a new treatment for hepatitis B, writes John George for the Philadelphia…
-
PROTECS Opens Innovation Center in Building Leased to Warminster’s Arbutus Headquarters
Life sciences real estate company PROTECS is acquiring a 35,000-square-foot research and development lab facility in Warminster. The building is the latest edition of…
-
Arbutus Biopharma CEO William Collier Announces Retirement As Company Cuts 24 Percent
William Collier, president and CEO of Warminster-based Arbutus Biopharma, will retire from his positions effective December 31, writes John George for the Philadelphia Business Journal.…
-
Doylestown Medical Nonprofit Names Physician, Advocate as Recipient of 2023 Community Commitment Award
A major medical nonprofit in Bucks County has just named an influential physician as their recipient for their yearly advocacy award. Staff writers for NewsWires…
-
Warminster’s Arbutus Biopharma Strikes Licensing-Partnering Deal with Chinese Pharma Firm
Arbutus Biopharma, Warminster, has entered a $300 million licensing and partnership deal with a Chinese biopharmaceutical firm. enters into $300M deal for experimental hepatitis B…
Founding Partners
Advertisement
Affiliate Partners
